ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Galena Biopharma, Inc." (GALE) Report Updated: Dec 15, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"Galena Biopharma, Inc." (GALE)

Rating: Sell Volatility: Aggressive
Total Grade: D Industry: Biotechnology
Competitors: REGN, MACK, CBST, ADMA

Stock Analysis

Rating: Monthly View

A
B
C
D
F
December January February March April May June July August September October November

Rating: Weekly View

This Week: D down no change
Last Week: D same no change
Two Weeks Ago: D up downgrade
service keys

"Galena Biopharma, Inc."© quotemedia

Company Profile

Galena Biopharma, Inc., a biotechnology company, engages in discovering, developing, and commercializing innovative therapies addressing unmet medical needs using targeted biotherapeutics. The company develops cancer therapeutics using peptide-based immunotherapy products, including its lead product candidate NeuVax (nelipepimut-S or E75), which is in Phase 3 PRESENT trial for the treatment of various cancers. It also develops Folate Binding Protein-E39, a targeted vaccine that is in Phase 1/2 clinical trial for the prevention of recurrence in gynecological cancers, such as ovarian, endometrial, and breast cancers. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Galena Biopharma, Inc. in September 2011. Galena Biopharma, Inc. was founded in 2003 and is based in Lake Oswego, Oregon.

Recent News: "Galena Biopharma, Inc."